Oncology

Trends across small cell lung cancer (SCLC) and diffuse large B-cell lymphoma (DLBCL) emphasize the need to further improve global treatment options.

Because these cells are present throughout the body, there may also be implications for other cancer types.

Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.

However, the monthly expenditure was not significantly associated with the financial incentives.

Pharmacists play a vital role in multidisciplinary health care teams by enhancing medication safety, optimizing therapeutic outcomes, expanding medication access, reducing costs, and improving patient education.

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

Data show that a child’s insurance status is independently associated with mortality after hematopoietic cell transplantation.

The guidelines were expanded to include the growing use of genetic testing within cancer prevention, screening, and treatment.

Rusfertide may sustain hematocrit levels in patients with polycythemia vera.

The risk of developing interstitial lung disease after immunotherapy was 6.5 times higher in individuals with high inflammation.

The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).

There were 2 main types of switches, including switching to rituximab subcutaneous and switching among different intravenous rituximab treatments.

ALE.P02 could provide further treatment options for advanced or metastatic anti–claudin-1+ squamous cancers.

The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.

Data from the BROADEN and PROGRESS studies were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from November 12 to 15.

Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

The indication is for adult and pediatric patients 1 year and older with a lysine methyltransferase 2A gene translocation.

The tablets become the first and only nilotinib with no mealtime restrictions indicated for this population.

Blaine Groat, PharmD, discusses the evolution of US Pharmacopeia (USP)'s drug standards, highlighting new compounding guidelines, as well as USP’s commitment to pharmacogenomics and upcoming opportunities for experts to contribute to personalized medicine standards.

White button mushroom can rebuild anti-cancer immune defense while slowing cancer growth.

The designation follows 2 previous orphan drug designations for pancreatic cancer and soft tissue sarcoma.

According to the study, 20% of patients with myeloproliferative neoplasms progress to blast phase.

Researchers applied extracellular vesicles retrieved from human red blood cells to serve as natural carrier to deliver the anti-cancer antisense oligonucleotides to the tumor site.

LBL-034 could be best in class in treating individuals with multiple myeloma.

If approved, zongertinib may be a new first-line oral tyrosine kinase inhibitor (TKI) for patients with HER2-mutated non-small cell lung cancer (NSCLC), a transformative step in TKI drug development.

If accepted, daratumumab would be the first approved treatment for smoldering multiple myeloma.

Brigimadlin is a new oral MDM2-p53 antagonist under investigation as a potential first-line therapy to improve outcomes for patients with advanced or metastatic dedifferentiated liposarcoma.

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.